宜宾线雕做鼻尖(宜宾开眼角图片) (今日更新中)

CANBERRA, April 14 (Xinhua) -- Scientists on Thursday expressed disappointment to the decision to cancel the long-running Australian Science Festival in Canberra.The festival has been operating during August for the past 19 years with free and ticketed science education activities.However, the festival organizers on Wednesday announced to halt this year's program after failing to secure support from the Australian Capital Territory state government in time to arrange events.According to Australian Science Communicators president, Jesse Shore, thousands of school children have attended the festival over its history to learn more about science as a career."It's encouraged other activities to join it, it was very important in getting National Science Week started, and that's stimulated a lot of other science communication activities," he told ABC News on Thursday.Shore said the decision to close it down is unfortunate as the event has been very influential and instrumental promoting science communications activities.He said he hopes that a number of people would gather together in a new partnership, with new ideas and hopefully a new funding base.

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.

BEIJING, Feb. 5 (Xinhua) - Beijing has seen the arrival of 660,000 tourists during the first three days of the Spring Festival holiday, from Feb. 2 to 4, said Beijing Municipal Bureau of Tourism officials late Friday.The tourism data was collected at the city' s 22 scenic spots.On February 4, official statistics showed that 40,000 tourists swarmed into the Palace Museum, repeating the number from last year' s national holiday, while about 14,500 ski-lovers enjoyed their time at 14 ski resorts in Beijing on the same day.Not only scenic spots, tourists also gravitated to some cultural venues in Beijing.The Beijing-based National Art Museum of China holds an exhibition on "donated masterpieces over the past 50 years (since its completion in 1952)" from Jan. 27 to Feb. 26 and spectators can visit, free of charge, during the Spring Festival holiday (between Feb. 3 and 9).On February 5, visitors queued up in a 200-meter long line waiting for check-in to the museum around 10 a.m.Wang Xiumei, 86, decided to visit the museum with her daughter ten days before."My husband and I were crazy about traditional Chinese paintings decades ago, I have to see some masterpieces today, rather than hearing about them later." Wang said.Hundreds of the nation' s art works are displayed in a dozen halls in the five-storey exhibition area, including oil paintings, ink paintings, wood block prints, shadow puppets, paper cuttings, clay sculptures and embroideries."I changed my mind and got off the bus on my way to a temple fair. My children and I want to see some elegant art works, as opposed to eating and playing during Spring Festival as before," said another citizen named Lu Hongmao.Big cities like Beijing, Shanghai and Guangzhou opened their sports venues to the public during the Spring Festival holiday.

BEIJING, Feb. 28 (Xinhua) -- Construction began on China's first low-speed maglev line Monday in Beijing, a project that will make China only the second country with a low-speed maglev line after Japan.The project marked China's ability to industrialize low-speed maglev technologies, said Chang Wensen, father of China's maglev technology and professor at the National University of Defense Technology.The 10-kilometer line runs from Shimenying Station in west Beijing's Mentougou District to Pingguoyuan Station in the Shijingshan District.The line, a section of Line S1 on the Beijing subway network, is expected to be completed in 2013 with a designed speed of 100 to 120 km per hour.China's research of maglev technologies was started in the 1980s by a team led by Chang Wensen. A 204-meter test line in central China's Hunan Province and a 1.5-km test line in north China's Hebei Province were built jointly by Beijing Maglev Technology Development Co., Ltd. and National University of Defense Technology.The intensity of the magnetic field had been tested as safe, according to a test report of Institute of Electrical Engineering, Chinese Academy of Sciences.The cost of the low-speed maglev line was estimated at 300 million yuan (4.6 million U.S. dollars) per kilometer, slightly more than light rail, but cheaper than the subway, which cost more than 600 million yuan a kilometer, said Li Jie, director of technology research center of National University of Defense Technology.The technology was also under consideration for Line 8 of the subway network in Shenzhen, in south China's Guangdong Province, said Liu Zhiming, board chairman of Beijing Maglev Technology Development Co., Ltd.."If Shenzhen adopts the technology, Line 8 will be China's second low-speed maglev line," he said.The world's first low-speed maglev line, at 8.9 km long, was completed in Japan in March 2005.Maglev, short for magnetic levitation, technology uses a large number of magnets to lift and propel a vehicle, making it faster, quieter and smoother than conventional wheeled transport systems.High-speed maglev vehicles can reach speeds of 450 km per hour and are usually used in long distance transportation, while low-speed maglev lines are usually used in short distance transportation.Construction also began on another seven lines on the Beijing subway network Monday.With an investment of 82 billion yuan (12 billion U.S. dollars), the eight lines will total 113.7 km in length and are expected to open from 2013 to 2015.Beijing has 16 lines under construction.

LOS ANGELES, April 14 (Xinhua) -- Customer complaints of an "uncharacteristic odor" prompted Johnson & Johnson to recall about 57,000 bottles of the prescription anti-seizure drug, Johnson & Johnson announced on Thursday.The recall affects two lots of the Topamax 100 mg tablets made by the company's Ortho-McNeil Neurologics division, Johnson & Johnson said.The drug was shipped and distributed between Oct. 19, 2010 and Dec. 28, 2010 in the United States and Puerto Rico.There were four consumer complaints about an odor believed to be caused by trace amounts of the chemical TBA (2,4,6 tribromoanisole), which is applied to wooden pallets used to transport and store packaging materials, Johnson & Johnson said.The recall is not expected to lead to a product shortage at the market, Ortho-McNeil Neurologics said.Similar complaints of a moldy, musty odor have led to the recalls of millions of bottles of Tylenol, Motrin and Benadryl products earlier.Last month, the U.S. government said it was taking over three Tylenol plants operated by McNeil, and the Food and Drug Administration launched a criminal investigation into safety issues at the factories, CNN reported.

来源：资阳报